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Renal involvement in acute lymphoblastic leukemia (ALL) occurs due to several factors including leukemic infiltration of the kidneys, therapy-related side effects 
such as tumor lysis syndrome, nephrotoxic drugs, and septicemias 
which may develop immune complex glomerulonephritis, 
and nephrotic syndrome (NS) [1]. In addition, uric acid 
nephropathy and toxicity due to chemotherapeutic agents, such 
as methotrexate, cisplatin, anthracyclines, and ifosfamide, may 
lead to renal damage in patients with ALL [2-5]. Reported 
morphological types of glomerulonephritis in these patients 
include membranous glomerulonephritis, focal segmental 
glomerulosclerosis (FSGS), and minimal change NS [6]. With 
rare exceptions, renal disease develops following the onset of 
ALL [7-10].
CASE REPORT
A 3-year-old boy presented with periorbital edema of 10 days 
duration. His physical examination showed: Weight 20.8 kg 
(> +3SD), height 96.8 cm (+1SD to +2SD), and blood 
pressure of 96/50 mmHg. There were no lymphadenopathy, 
hepatosplenomegaly, bruising, or petechiae. Urinalysis showed 
4+ (>1000 mg/dl) proteinuria - whereas serum analysis only 
showed low total serum protein (41 g/l; normal=60–85 g/l) and 
low albumin (14 g/l; normal=35–55 g/l) levels. Complete blood 
count (CBC) was within the normal limits without any abnormal 
cells on the peripheral blood smear. On the basis of clinical 
presentation and investigation findings, the diagnosis of NS was 
made.
Treatment of NS was commenced with daily prednisone 
(2 mg/kg/day). Following 6 weeks of daily prednisone 
therapy, nephrotic range proteinuria and clinical symptoms 
of edema persisted, and a percutaneous renal biopsy was 
performed at 8th week. A total of 30 glomeruli were available 
for the examination by light microscopy; 14 of these were 
demonstrated segmental glomerulosclerosis of varying degree; 
three glomeruli had global sclerosis. The glomeruli with 
segmental sclerosis were dispersed throughout the core of the 
biopsy specimen [Fig. 2]. A mild degree of interstitial fibrosis 
and tubular dropout (a process that leads to progressive 
glomerular loss of activated tubular cells which produce 
cytokines, support inflammatory responses, and dedifferentiate 
results in nephron loss), along with mononuclear cell infiltrate, 
were noted. No evidence of neoplastic infiltration by malignant 
cells was noted.
At the 10th week, the patient had cushingoid features with 
pretibial and periorbital edema; urinalysis showed proteinuria 
of 3+ (>300 mg/dl) and serum albumin of 21 g/l. CBC showed 
WBC 12.1×109/l, hematocrit 44.2%, and platelet count 350×109/l. 
A trial with cyclosporin was initiated due to the lack of response to 
prednisone with the starting dose of 5 mg/kg/day. Prednisone was 
continued in a tapering dose, and the patient received enalapril 
and furosemide as adjunctive therapies. 1 month after starting 
cyclosporine, the baby no longer had edema, and the spot urinary 
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protein/creatinine ratio was <2 with serum total protein of 70 g/l, 
and albumin of 38 g/l.
14 months after the initial diagnosis of NS, the patient was 
presented to the emergency department with fever, difficulty 
in breathing, generalized edema, and body pain [Fig.1]. 
Clinical examination showed pallor without lymphadenopathy, 
hepatosplenomegaly, petechiae, or purpura. CBC showed 
WBC 175×109/l (normal=3.5–12.0×109/L), hemoglobin 
23 g/l (normal=107–134 g/l), and a platelet count of 20×109/l 
(normal=150–400×109/L). Other significant laboratory studies 
included blood urea nitrogen 52.8 mmol/l (normal=8.0–16.4 
mmol/l) and creatinine 141 μmol/l (normal=50–110 μmol/l). 
Peripheral smear showed blast cells >80%; [Fig. 3] a bone marrow 
aspiration showed complete replacement of the marrow with L1 
lymphoblasts, consistent with a diagnosis of ALL [Fig. 4]. The 
patient demised from septicemia and multiorgan failure.
DISCUSSION
The malignancies, commonly associated with NS, include 
Hodgkin and non-Hodgkin lymphomas, chronic lymphocytic 
leukemia, and acute myelogenous leukemia [5]. In the pediatric 
population, scanty number of cases of ALL has been reported 
in association with NS. The main line of management in 
neoplastic and non-neoplastic disorders includes cytotoxic 
immunosuppressive agents, which plays an important role in the 
treatment of these disorders.
Alkylating agents, such as cyclophosphamide and 
chlorambucil, are known to induce secondary malignancies, in 
particular, leukemia [11]. In some reported cases, cyclosporine has 
been associated with an increased risk of malignancies [12-14]. 
Malignancy as a complication of NS, even following treatment 
with cytotoxic drugs, is uncommon. Berns et al. [14] did not 
vttreport any cases of malignancy on follow-up of 20 such patients. 
A review of the database, available at Medline/PubMed from 1970 
to 2017 showed that NS preceding the diagnosis of ALL has been 
reported in only five pediatric patients. Among all the reported 
cases, the time span between the onset of NS and diagnosis of 
Figure 1: A 3-year-old boy of nephrotic syndrome with acute 
lymphoblastic leukemia
Figure 2: Renal biopsy findings demonstrating segmental 
glomerulosclerosis of varying degree, dispersed throughout the core 
of the biopsy specimen, including in the superficial cortex
Figure 4: Bone marrow aspiration and examination showing 
markedly hyperplasia with about 90% blast cells suggestive of acute 
lymphoblastic leukemia
Figure 3: Peripheral blood smear showing blast cells with minimal 
cytoplasm, variable nuclear size, and chromatin density and irregular 
nuclear contour suggestive of acute lymphoblastic leukemia
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ALL was under 1 year, except the one patient in which ALL was 
diagnosed after the 7 years of the initial diagnosis of NS [7-10].
The main pathogenesis of ALL in children with NS has not 
been determined. There may be three possibilities in support of 
it; first, the children with NS may have a pre-existing leukemic 
state, which was masked by prednisone therapy. It is conceivable 
that abnormal cells were present in the bone marrow but were 
below the established level necessary for the diagnosis of ALL. 
The leukemia could have partially treated by prednisone therapy, 
thus delaying the final diagnosis. Total replacement of the bone 
marrow occurred within 8–12 weeks as the doubling time of pre-B 
leukemic cells would have required approximately 24 h [15], and 
overt leukemia was diagnosed in all but one patient after more than 
4 months from the diagnosis of NS. The second possibility, when 
there was disruption of normal immune surveillance caused by 
immunosuppressive agents could allow an abnormal clone to go 
undetected and proliferate. Outgrowth of abnormal cells has been 
indicated as a crucial factor in the progression of malignancies [16].
Last possibility was that an underlying defect in T-cell 
function or T-/B- cell cooperation could account for both NS and 
the risk of malignancies in later life. Shalhoub [17] suggested that 
NS is a disorder of lymphocyte function and Fiser et al. [18] have 
demonstrated abnormal T-lymphocyte subsets in children with 
NS. FSGS has been reported as the main pathology in patients 
who develop ALL with pre-existing NS [5]. There was no clinical 
benefit of corticosteroid therapy in such patients [6-9].
CONCLUSION
The treatment of childhood NS with cytotoxic drugs and 
calcineurin inhibitors is well accepted. The risk of malignancy with 
such therapy has been generally considered to be low. However, 
the presence of persistent abnormalities in the hematological 
profile of nephrotic patients undergoing immunosuppressive 
therapy needs closer evaluation for underlying leukemia. A lower 
threshold for bone marrow aspiration in such patients should be 
considered for early detection and treatment of leukemia.
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